08:38 AM EDT, 06/04/2025 (MT Newswires) -- Vigil Neuroscience ( VIGL ) said Wednesday it is discontinuing the phase 2 long-term extension study of iluzanebart in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, or ALSP.

The move is based on the results of its phase 2 proof-of-concept trial, which showed no beneficial effects on biomarker or clinical efficacy endpoints, although iluzanebart showed a favorable safety, tolerability and pharmacokinetic profile in the 20 mg/kg and 40 mg/kg dose groups, according to the company.

Vigil Chief Executive Ivana Magovcevic-Liebisch said, "this is not the data outcome we hoped to see for our iluzanebart program and our patients," but the data collected from the trial helped to increase awareness of the neurodegenerative disease.